Page 1

QI FINANCIAL SUMMARY Figures within parentheses refer to the preceding year . First quarter ■ ' Implantica INTERIM REPORT JAN – MAR 2021 ■ Net sales amounted to TEUR 82 ( 23 ) . Operating loss ( EBIT ) increased to TEUR 2,279 ( 1,397 ) . Loss after tax amounted to TEUR 1,966 ( 1,252 ) . Basic and diluted loss per Class A share amounted to EUR 0.03 ( 0.03 ) . SIGNIFICANT EVENTS In the first quarter of 2021 ▪ Implantica is able to sell RefluxStop ™ in the UK with reimbursement and is now expanding the sales organization in the UK . In Germany , Implantica has received its own Operation and Procedure Classification System ( OPS ) code and a reimbursement Diagnosis Related Group ( DRG ) for RefluxStop ™ . This is a milestone in Germany . Applications for regulatory approval of RefluxStop ™ are ongoing in 30 countries around the world . Implantica has had two meetings with the FDA . After the initial pre - submission meeting for Reflux Stop ™ , the FDA requested a second follow - up meeting with their surgical expertise . The next step will be a pre - submission supplement . Implantica has been accelerating the integration of the eHealth platform technology in its pipeline products and is utilizing the momentum in the digital industry to maintain the goal to be in the forefront of the eHealth transformation . Thanks to excellent clinical results , several international leading anti - reflux surgeons have decided to start to use RefluxStop ™ . Q121 INTERIM REPORT IMPLANTICA After the end of the period RefluxStop ™ to be implemented at one of the largest hospitals in Europe , University Hospital AKH Vienna . Professor Schoppmann , one of Europe's leading anti - reflux surgeons , will start to operate with Reflux Stop ™ and conduct a study with 25-30 reflux patients . ■ Liquid funds as at the end of the period amounted to MEUR 93.3 . No interest - bearing debt at end of the period . I In Sweden , which is Implantica's second home market , RefluxStop ™ can be implanted with reimbursement by public healthcare . Discussions have been nitiated with key centers in Sweden . Implantica has started to commercialize RefluxStop ™ on a reimbursed basis in Italy and Spain based on local and regional hospital agreements . Implantica successfully raised approximately SEK 600 million in a directed new share issue to speed up the commercialization of RefluxStop ™ and to accelerate bringing our eHealth platform technology to the market . Implantica is reinforcing its management with additional important core competencies to build an even stronger team supporting the Company's future growth .